Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea

Ji Young Kim, Seung Ju Kim, Chung Mo Nam, Ki Tae Moon, Eun Cheol Park

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: To ensure effective prescription practices and reduce diabetes-related pharmaceutical expenditures, Korea adopted a clinical practice guideline for the reimbursement system. Health care providers cannot receive reimbursement from National Health Insurance(NHI) unless it is for an appropriate prescription under the predefined clinical condition. The aim of this study was to evaluate prescription patterns in oral hypoglycemic agents, costs and effects on patient care since the introduction of the diabetes reimbursement restriction. Methods: We used claim data from 2008 to 2013, which included 26 315 diabetes patients and 9907 hospitals. An interrupted time series study design using generalized estimating equations was used to evaluate changes in patterns of single and combination therapy, brand name drug prescriptions, cost and hospital admission following the reimbursement restriction. Results: Following reimbursement restriction initiation, we found a statistically significant decrease in the average prescription rate of brand name drugs (-6.2%), whereas single therapy prescription increased (9.9%). There was also a reduction in trend change in the monthly prescription rate for combination therapy (-1.7%) and brand name drugs (-0.8%). For single therapy, the trend change in prescription rate increased after the intervention (0.8%). A reduction of trend change in pharmaceutical costs (-0.3%) was observed. However, we did not find a significant change in hospital admission for diabetes. Conclusions: Reimbursement restriction affects both pharmaceutical costs and physicians' decisions to prescribe oral hypoglycemic agents. We did not observe a significant reduction in quality of care following the intervention. Collectively, these findings indicate that reimbursement restriction has improved effective drug utilization and decreased health expenditures.

Original languageEnglish
Pages (from-to)209-214
Number of pages6
JournalEuropean journal of public health
Volume28
Issue number2
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Prescription Drugs
Quality of Health Care
Korea
Health Expenditures
Prescriptions
Hypoglycemic Agents
Names
Pharmaceutical Preparations
Costs and Cost Analysis
Drug Utilization
Drug Prescriptions
Drug Costs
National Health Programs
Therapeutics
Practice Guidelines
Health Personnel
Patient Care
Physicians

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

@article{71925239cb764e24900cef1770924793,
title = "Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea",
abstract = "Background: To ensure effective prescription practices and reduce diabetes-related pharmaceutical expenditures, Korea adopted a clinical practice guideline for the reimbursement system. Health care providers cannot receive reimbursement from National Health Insurance(NHI) unless it is for an appropriate prescription under the predefined clinical condition. The aim of this study was to evaluate prescription patterns in oral hypoglycemic agents, costs and effects on patient care since the introduction of the diabetes reimbursement restriction. Methods: We used claim data from 2008 to 2013, which included 26 315 diabetes patients and 9907 hospitals. An interrupted time series study design using generalized estimating equations was used to evaluate changes in patterns of single and combination therapy, brand name drug prescriptions, cost and hospital admission following the reimbursement restriction. Results: Following reimbursement restriction initiation, we found a statistically significant decrease in the average prescription rate of brand name drugs (-6.2{\%}), whereas single therapy prescription increased (9.9{\%}). There was also a reduction in trend change in the monthly prescription rate for combination therapy (-1.7{\%}) and brand name drugs (-0.8{\%}). For single therapy, the trend change in prescription rate increased after the intervention (0.8{\%}). A reduction of trend change in pharmaceutical costs (-0.3{\%}) was observed. However, we did not find a significant change in hospital admission for diabetes. Conclusions: Reimbursement restriction affects both pharmaceutical costs and physicians' decisions to prescribe oral hypoglycemic agents. We did not observe a significant reduction in quality of care following the intervention. Collectively, these findings indicate that reimbursement restriction has improved effective drug utilization and decreased health expenditures.",
author = "Kim, {Ji Young} and Kim, {Seung Ju} and Nam, {Chung Mo} and Moon, {Ki Tae} and Park, {Eun Cheol}",
year = "2018",
month = "4",
day = "1",
doi = "10.1093/eurpub/ckx168",
language = "English",
volume = "28",
pages = "209--214",
journal = "European Journal of Public Health",
issn = "1101-1262",
publisher = "Oxford University Press",
number = "2",

}

Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea. / Kim, Ji Young; Kim, Seung Ju; Nam, Chung Mo; Moon, Ki Tae; Park, Eun Cheol.

In: European journal of public health, Vol. 28, No. 2, 01.04.2018, p. 209-214.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea

AU - Kim, Ji Young

AU - Kim, Seung Ju

AU - Nam, Chung Mo

AU - Moon, Ki Tae

AU - Park, Eun Cheol

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: To ensure effective prescription practices and reduce diabetes-related pharmaceutical expenditures, Korea adopted a clinical practice guideline for the reimbursement system. Health care providers cannot receive reimbursement from National Health Insurance(NHI) unless it is for an appropriate prescription under the predefined clinical condition. The aim of this study was to evaluate prescription patterns in oral hypoglycemic agents, costs and effects on patient care since the introduction of the diabetes reimbursement restriction. Methods: We used claim data from 2008 to 2013, which included 26 315 diabetes patients and 9907 hospitals. An interrupted time series study design using generalized estimating equations was used to evaluate changes in patterns of single and combination therapy, brand name drug prescriptions, cost and hospital admission following the reimbursement restriction. Results: Following reimbursement restriction initiation, we found a statistically significant decrease in the average prescription rate of brand name drugs (-6.2%), whereas single therapy prescription increased (9.9%). There was also a reduction in trend change in the monthly prescription rate for combination therapy (-1.7%) and brand name drugs (-0.8%). For single therapy, the trend change in prescription rate increased after the intervention (0.8%). A reduction of trend change in pharmaceutical costs (-0.3%) was observed. However, we did not find a significant change in hospital admission for diabetes. Conclusions: Reimbursement restriction affects both pharmaceutical costs and physicians' decisions to prescribe oral hypoglycemic agents. We did not observe a significant reduction in quality of care following the intervention. Collectively, these findings indicate that reimbursement restriction has improved effective drug utilization and decreased health expenditures.

AB - Background: To ensure effective prescription practices and reduce diabetes-related pharmaceutical expenditures, Korea adopted a clinical practice guideline for the reimbursement system. Health care providers cannot receive reimbursement from National Health Insurance(NHI) unless it is for an appropriate prescription under the predefined clinical condition. The aim of this study was to evaluate prescription patterns in oral hypoglycemic agents, costs and effects on patient care since the introduction of the diabetes reimbursement restriction. Methods: We used claim data from 2008 to 2013, which included 26 315 diabetes patients and 9907 hospitals. An interrupted time series study design using generalized estimating equations was used to evaluate changes in patterns of single and combination therapy, brand name drug prescriptions, cost and hospital admission following the reimbursement restriction. Results: Following reimbursement restriction initiation, we found a statistically significant decrease in the average prescription rate of brand name drugs (-6.2%), whereas single therapy prescription increased (9.9%). There was also a reduction in trend change in the monthly prescription rate for combination therapy (-1.7%) and brand name drugs (-0.8%). For single therapy, the trend change in prescription rate increased after the intervention (0.8%). A reduction of trend change in pharmaceutical costs (-0.3%) was observed. However, we did not find a significant change in hospital admission for diabetes. Conclusions: Reimbursement restriction affects both pharmaceutical costs and physicians' decisions to prescribe oral hypoglycemic agents. We did not observe a significant reduction in quality of care following the intervention. Collectively, these findings indicate that reimbursement restriction has improved effective drug utilization and decreased health expenditures.

UR - http://www.scopus.com/inward/record.url?scp=85045944827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045944827&partnerID=8YFLogxK

U2 - 10.1093/eurpub/ckx168

DO - 10.1093/eurpub/ckx168

M3 - Article

C2 - 29579210

AN - SCOPUS:85045944827

VL - 28

SP - 209

EP - 214

JO - European Journal of Public Health

JF - European Journal of Public Health

SN - 1101-1262

IS - 2

ER -